WAS
VRTX icon

Wealth Advisory Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Advisory Solutions’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-503
Closed -$210K – 135
2024
Q1 		$210K Buy
+503
New +$213K 0.05% 119

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wealth Advisory Solutions's VRTX Position: Q2 2024 in Review

Wealth Advisory Solutions sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 503 shares — an estimated $210K sold.

Wealth Advisory Solutions first reported a position in VRTX in Q1 2024 and held it in 1 quarter. The position peaked at $210K in Q1 2024. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Wealth Advisory Solutions reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wealth Advisory Solutions sold 503 Vertex Pharmaceuticals shares in Q2 2024, an estimated $210K.
  • Wealth Advisory Solutions first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Wealth Advisory Solutions's Vertex Pharmaceuticals position peaked at $210K in Q1 2024.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Wealth Advisory Solutions's 13F filing for Q2 2024, filed 26 Jul 2024.